LSD1-targeted inhibitors are known to differentially target pluripotent cancer cells, including teratocarcinoma, embryonic carcinoma, and seminoma or embryonic stem cells that express the core stem cell transcriptional factor SOX2, while having minimal growth-inhibitory effects on non-pluripotent or normal somatic cells [35,36,37,38,39,40,41,42]. Here, SOX2 is linked to teratocarcinoma.